Truxima maintenance therapy is indicated for the treatment of follicular lymphoma patients responding to induction therapy.

INN:

Subtype:

Follicular Lymphoma (FL)

License:

EMA

Class:

CD20 monoclonal antibody

R/R

SmPC: https://www.medicines.org.uk/emc/medicine/33201

 

1. Approved Labelling

Truxima maintenance therapy is indicated for the treatment of follicular lymphoma patients responding to induction therapy.

2. Treatment Regimen

The recommended dose of Truxima used as a maintenance treatment for patients with relapsed/refractory follicular lymphoma who have responded to induction treatment is: 375mg/m2 body surface area once every 3 months (starting 3 months after the last dose of induction therapy) until disease progression or for a maximum period of two years.

3. AE/Warnings

Please see section 4.4 of the SmPC

All content on this site is intended for healthcare professionals only. If you are a patient or carer, please visit the Lymphoma Coalition.